The report "Biobanking Market by Product (Equipment, Consumables, Software), Services (Virtual), Operation (Automated), Workflow (Storage, Collection, Transport), Sample (Blood, Cell Lines, Nucleic Acids), Application, Ownership, End User - Global Forecast to 2030", is projected to reach USD 11.82 billion by 2030 from an estimated USD 7.65 billion in 2025, at a CAGR of 9.1% during the forecast period.
Browse over 741 market data tables and 64 figures spread through more than 491 pages and in-depth TOC on “Biobanking Market -Global Forecast to 2030." View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biobanking-devices-market-594.html
Some factors contributing to the growth of the global biobanking market include growing focus on precision or personalized medicine, continuously expanding cell & gene therapy pipeline, and end-to-end automation for sample handling & storage. Additionally, the focus on sustainability and green-lab solutions offers growth opportunities for market players. However, long-term funding stability for public biobanks is a challenge faced by the market.
By product, the equipment segment accounted for the largest share of the biobanking market in 2024.
By product, the biobanking market is segmented into equipment and consumables. The equipment market is further split into freezers & refrigerators, temperature & humidity control systems, cryogenic storage systems, thawing equipment, alarm & monitoring systems, and other equipment. Freezers & refrigerators held the largest share of the biobanking equipment market in 2024 as they are essential to the core operations of any biobank, ensuring the long-term storage and preservation of biological samples such as blood, tissues, and DNA. Given the nature of biobank samples, maintaining optimal temperature conditions is critical to preserving sample integrity for future research, diagnostics, and therapeutic development. Cryogenic freezers, in particular, are indispensable for the preservation of cell lines, stem cells, and genetic materials, often requiring ultra-low temperatures to maintain viability for years.
By end user, the pharmaceutical & biotechnology companies & CROs segment is estimated to register the highest growth in the biobanking services market during the forecast period.
Based on end user, the biobanking services market is segmented into pharmaceutical & biotechnology companies & CROs, and academic & research institutes. The pharmaceutical & biotechnology companies & CROs segment is estimated to register the highest growth rate during the forecast period, driven by the rising demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. These companies are expanding their therapeutic offerings, which are dependent on cell lines, and clinical sample management is highly demanded by these end users.
The Asia Pacific region is expected to register the highest CAGR during the forecast period.
Based on the region, the biobanking market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to register the highest growth rate during the forecast period, since countries like China, India, and Japan ramp up their research capabilities, biobanks in the region are gaining momentum, becoming critical to advancing drug discovery, clinical trials, and population-based health studies. The growing prevalence of chronic diseases, coupled with the region’s aging population, has spurred a need for comprehensive biobanking solutions to support healthcare innovations and research into disease prevention and treatment.
The key players in the biobanking market include Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), and Cryoport (US), among other players.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/